UK 356618
Based on 7 publication(s) in Google Scholar
UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC50 of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with MMP-3.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.51%
- CAS No.: 230961-08-7
- Formule: C34H43N3O4
- Masse moléculaire:557.72
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) UK 356618
More- Acta Biomater. 2024 Mar 1:176:405-416. [Abstract]
- Antioxidants (Basel). 2023 Sep 25;12(10):1800. [Abstract]
- J Bone Miner Res. 2023 Jan;38(1):214-227. [Abstract]
- Life Sci. 2025 Mar 18:123570. [Abstract]
- PLoS Comput Biol. 2026 May 29;22(5):e1014323. [Abstract]
- Immunobiology. 2025 May 29;230(4):152918. [Abstract]
- PLoS One. 2022 Nov 29;17(11):e0278220. [Abstract]
Customer Validation & Images
-
IF
Activité biologique
|
MMP-3 5.9 nM (IC50) |
MMP-13 73 nM (IC50) |
MMP-9 0.84 μM (IC50) |
MMP-2 1.79 μM (IC50) |
MMP-14 1.9 μM (IC50) |
MMP-1 51 μM (IC50) |
UK 356618 is more widely profiled against other MMPs[1].
MMP-13 is closely involved in IL-6 or TNF-α increasing tumor metastasis. MMP-13 deficiency abrogate TNF-α effect on lung cancer cell migration. UK 356618 treatment efficiently abolished the effect of TNF-α on cell migration in NCI-H446 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hyperglycemic male Wistar rats injected with middle cerebral artery occlusion (MCAO)[3]
-
Dosage:15 mg/kg
-
Administration:Intravenous injection; for 24 h or 7 days
-
Result:Significantly reduced MMP3 activity in the brain.
Chemical Information
-
CAS No. 230961-08-7
-
Appearance Solid
-
Masse moléculaire 557.72
-
Formule C34H43N3O4
-
Color White to light yellow
-
SMILES
CC1=C(C2=CC=CC=C2)C=CC(CCC[C@H](CC(NO)=O)C(N[C@@H](C(C)(C)C)C(N[C@@H](C3=CC=CC=C3)C)=O)=O)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Acta Biomater
A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells. [Abstract]2024 Mar 1:176:405-416. PMID: 38185231 -
Antioxidants (Basel)
DUOX2-Induced Oxidative Stress Inhibits Intestinal Angiogenesis through MMP3 in a Low-Birth-Weight Piglet Model. [Abstract]2023 Sep 25;12(10):1800. PMID: 37891879 -
J Bone Miner Res
Osteoblastic STAT3 is Crucial for Orthodontic Force Driving Alveolar Bone Remodeling and Tooth Movement. [Abstract]2023 Jan;38(1):214-227. PMID: 36370067
UK 356618 purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2023 Jan;38(1):214-227. [Abstract]
The TRAP staining exhibits a reduced number of osteoclasts in the coculturing system of BMSCs treated with the MMP3 inhibitor UK 356618 (UK) and Raw 264.7 cells in response to the mechanical force.
-
Life Sci
MMP3 as a new target of Danshensu/tetramethylpyrazine derivative for attenuating cardiac fibrosis post-myocardial infarction. [Abstract]2025 Mar 18:123570. PMID: 40113078 -
PLoS Comput Biol
A prototype-augmented graph representation learning framework for identifying brain disorder-associated genes and facilitating drug repurposing. [Abstract]2026 May 29;22(5):e1014323. PMID: 42213730 -
Immunobiology
2025 May 29;230(4):152918. PMID: 40472707 -
PLoS One
Interleukin-1β triggers matrix metalloprotease-3 expression through p65/RelA activation in melanoma cells. [Abstract]2022 Nov 29;17(11):e0278220. PMID: 36445856
Solvant et solubilité
DMSO : 25 mg/mL (44.83 mM; ultrasonic and adjust pH to 2 with 1M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Fray MJ, et al. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorg Med Chem Lett. 2001 Feb 26;11(4):571-4. [Content Brief]
[2]. Yan HQ, et al. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells. Oncotarget. 2016 Sep 20;7(38):62070-62083. [Content Brief]
[3]. Hafez S, et al. Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke. Stroke. 2016 Mar;47(3):843-51. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7930 mL | 8.9651 mL | 17.9301 mL | 44.8254 mL |
| 5 mM | 0.3586 mL | 1.7930 mL | 3.5860 mL | 8.9651 mL | |
| 10 mM | 0.1793 mL | 0.8965 mL | 1.7930 mL | 4.4825 mL | |
| 15 mM | 0.1195 mL | 0.5977 mL | 1.1953 mL | 2.9884 mL | |
| 20 mM | 0.0897 mL | 0.4483 mL | 0.8965 mL | 2.2413 mL | |
| 25 mM | 0.0717 mL | 0.3586 mL | 0.7172 mL | 1.7930 mL | |
| 30 mM | 0.0598 mL | 0.2988 mL | 0.5977 mL | 1.4942 mL | |
| 40 mM | 0.0448 mL | 0.2241 mL | 0.4483 mL | 1.1206 mL |
UK 356618 Related Classifications
HY-107394 Related Classifications
Powered by Bioz